产β-内酰胺类抗生素耐药阴沟肠杆菌外膜孔蛋白改变的发生率
Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes.
作者信息
Charrel R N, Pagès J M, De Micco P, Mallea M
机构信息
Enveloppe et perméation chez les entérobactéries, UPR 9027, I.F.R.I, Centre National de la Recherche Scientifique, Marseille, France.
出版信息
Antimicrob Agents Chemother. 1996 Dec;40(12):2854-8. doi: 10.1128/AAC.40.12.2854.
Abstract
We evaluated the prevalence of impermeability as a mechanism associated with resistance against beta-lactam antibiotics in members of the family Enterobacteriaceae. During a 1-year period, 80 strains were selected from 3,110 routinely isolated strains according to their noticeable cross-resistance pattern to cephalosporins. They were tested for (i) outer membrane nonspecific porins involved in the entry of small hydrophilic molecules; (ii) the MICs of cefepime, cefotaxime, imipenem, and moxalactam; and (iii) beta-lactamase production. Immunological investigations using specific probes showed that 23 of 80 strains presented an alteration of the porin content, most of them expressing an additional resistance mechanism. The prevalence of this porin-deficient phenotype is especially high in Enterobacter aerogenes and concerns 6.4% of the clinical isolates.
摘要
我们评估了通透性缺失作为一种与肠杆菌科细菌对β-内酰胺类抗生素耐药相关机制的流行情况。在为期1年的时间里，根据80株菌株对头孢菌素显著的交叉耐药模式，从3110株常规分离菌株中挑选出来。对它们进行了以下检测：(i) 参与小的亲水分子进入的外膜非特异性孔蛋白；(ii) 头孢吡肟、头孢噻肟、亚胺培南和美洛培南的最低抑菌浓度（MIC）；以及(iii) β-内酰胺酶的产生。使用特异性探针进行的免疫学研究表明，80株菌株中有23株呈现孔蛋白含量改变，其中大多数表达了额外的耐药机制。这种孔蛋白缺陷表型在产气肠杆菌中的流行率特别高，占临床分离株的6.4%。
相似文献
1
Prevalence of outer membrane porin alteration in beta-lactam-antibiotic-resistant Enterobacter aerogenes.
Antimicrob Agents Chemother. 1996 Dec;40(12):2854-8. doi: 10.1128/AAC.40.12.2854.
2
Porin alteration and active efflux: two in vivo drug resistance strategies used by Enterobacter aerogenes.
Microbiology (Reading). 1998 Nov;144 ( Pt 11):3003-3009. doi: 10.1099/00221287-144-11-3003.
3
Successive emergence of extended-spectrum beta-lactamase-producing and carbapenemase-producing Enterobacter aerogenes isolates in a university hospital.
J Clin Microbiol. 2008 Mar;46(3):1037-44. doi: 10.1128/JCM.00197-07. Epub 2008 Jan 30.
4
Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
J Antimicrob Chemother. 1985 Jun;15 Suppl C:119-32. doi: 10.1093/jac/15.suppl_c.119.
5
Outer membrane protein profiles of clonally related Klebsiella pneumoniae isolates that differ in cefoxitin resistance.
FEMS Microbiol Lett. 2005 Feb 1;243(1):197-203. doi: 10.1016/j.femsle.2004.12.023.
6
Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles.
Antimicrob Agents Chemother. 2000 Sep;44(9):2534-6. doi: 10.1128/AAC.44.9.2534-2536.2000.
7
Contribution of beta-lactamase hydrolysis and outer membrane permeability to ceftriaxone resistance in Enterobacter cloacae.
Antimicrob Agents Chemother. 1987 Oct;31(10):1589-95. doi: 10.1128/AAC.31.10.1589.
8
Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK.
J Antimicrob Chemother. 2009 Apr;63(4):659-67. doi: 10.1093/jac/dkp029. Epub 2009 Feb 20.
9
Extended-spectrum beta-lactamases and the permeability barrier.
Clin Microbiol Infect. 2008 Jan;14 Suppl 1:82-9. doi: 10.1111/j.1469-0691.2007.01860.x.
10
Antibiotic susceptibility and beta-lactamase production in clinical isolates of Enterobacter spp.
APMIS. 1990 May;98(5):462-70.
引用本文的文献
1
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens.
NPJ Antimicrob Resist. 2023 Dec 20;1(1):17. doi: 10.1038/s44259-023-00016-1.
2
Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales.
Pharmacy (Basel). 2024 Sep 21;12(5):142. doi: 10.3390/pharmacy12050142.
3
Study of Antimicrobial Resistance (AMR) in spp. in India.
Recent Adv Antiinfect Drug Discov. 2024;19(3):182-196. doi: 10.2174/0127724344268156231129095108.
4
Cephalosporin resistance, tolerance, and approaches to improve their activities.
J Antibiot (Tokyo). 2024 Mar;77(3):135-146. doi: 10.1038/s41429-023-00687-y. Epub 2023 Dec 19.
5
High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production.
Open Forum Infect Dis. 2023 Jan 25;10(3):ofad034. doi: 10.1093/ofid/ofad034. eCollection 2023 Mar.
6
Cephalosporin translocation across enterobacterial OmpF and OmpC channels, a filter across the outer membrane.
Commun Biol. 2022 Oct 5;5(1):1059. doi: 10.1038/s42003-022-04035-y.
7
Identification of Multiple Low-Level Resistance Determinants and Coselection of Motility Impairment upon Sub-MIC Ceftriaxone Exposure in Escherichia coli.
mSphere. 2021 Dec 22;6(6):e0077821. doi: 10.1128/mSphere.00778-21. Epub 2021 Nov 17.
8
Prioritization of potential drug targets and antigenic vaccine candidates against using the computational subtractive proteome-driven approach.
J Proteins Proteom. 2021;12(3):201-211. doi: 10.1007/s42485-021-00068-9. Epub 2021 Jul 16.
9
Transporters Involved in the Biogenesis and Functionalization of the Mycobacterial Cell Envelope.
Chem Rev. 2021 May 12;121(9):5124-5157. doi: 10.1021/acs.chemrev.0c00869. Epub 2020 Nov 10.
10
Strategic Moves of "Superbugs" Against Available Chemical Scaffolds: Signaling, Regulation, and Challenges.
ACS Pharmacol Transl Sci. 2020 Apr 13;3(3):373-400. doi: 10.1021/acsptsci.0c00005. eCollection 2020 Jun 12.
本文引用的文献
1
Crucial domains are conserved in Enterobacteriaceae porins.
FEMS Microbiol Lett. 1996 Feb 1;136(1):91-7. doi: 10.1111/j.1574-6968.1996.tb08030.x.
2
Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum beta-lactamase to other members of the family enterobacteriaceae.
J Clin Microbiol. 1996 Jan;34(1):76-9. doi: 10.1128/jcm.34.1.76-79.1996.
3
Biochemical properties of a carbapenem-hydrolyzing beta-lactamase from Enterobacter cloacae and cloning of the gene into Escherichia coli.
Antimicrob Agents Chemother. 1993 May;37(5):939-46. doi: 10.1128/AAC.37.5.939.
4
Clinical and bacteriological study of nosocomial infections due to Enterobacter aerogenes resistant to imipenem.
J Clin Microbiol. 1993 Jan;31(1):123-7. doi: 10.1128/jcm.31.1.123-127.1993.
5
An overview of nosocomial infections, including the role of the microbiology laboratory.
Clin Microbiol Rev. 1993 Oct;6(4):428-42. doi: 10.1128/CMR.6.4.428.
6
Resistance to antibiotics mediated by target alterations.
Science. 1994 Apr 15;264(5157):388-93. doi: 10.1126/science.8153626.
7
Prevention of drug access to bacterial targets: permeability barriers and active efflux.
Science. 1994 Apr 15;264(5157):382-8. doi: 10.1126/science.8153625.
8
Inactivation of antibiotics and the dissemination of resistance genes.
Science. 1994 Apr 15;264(5157):375-82. doi: 10.1126/science.8153624.
9
Cefepime: overview of activity in vitro and in vivo.
J Antimicrob Chemother. 1993 Nov;32 Suppl B:87-94. doi: 10.1093/jac/32.suppl_b.87.
10
In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
J Antimicrob Chemother. 1993 Nov;32 Suppl B:21-9. doi: 10.1093/jac/32.suppl_b.21.
Zotero 插件